Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China SXT PharmaceuticalsSXTC -8.13% EV-to-EBITDA is 4.07 as of Aug. 04, 2026, which is 5% below its 10-year median of 4.28. The stock has 8 warning signs investors should review. Among 746 Drug Manufacturers companies, China SXT Pharmaceuticals ranks better than 90.75% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, China SXT Pharmaceuticals's enterprise value is $-24.42 Mil.
China SXT Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-6.00 Mil. Therefore, China SXT Pharmaceuticals's EV-to-EBITDA for today is 4.07.
The historical rank and industry rank for China SXT Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
SXTC'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 2.35 Med: 4.28 Max: 6.83
Current: 4.07
During the past 10 years, the highest EV-to-EBITDA of China SXT Pharmaceuticals was 6.83. The lowest was 2.35. And the median was 4.28.
SXTC's EV-to-EBITDA is ranked better than 90.75% of 746
companies
in the Drug Manufacturers industry
Industry Median: 13.08
vs SXTC: 4.07
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
China SXT Pharmaceuticals (NAS:SXTC) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
China SXT Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
China SXT Pharmaceuticals's share price for today is $0.0689.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. China SXT Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-9.130.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, China SXT Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China SXT Pharmaceuticals EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China SXT Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where China SXT Pharmaceuticals's EV-to-EBITDA falls into.
China SXT Pharmaceuticals's current Enterprise Value is $-24.42 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. China SXT Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-6.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China SXT Pharmaceuticals (SXTC) has a EV-to-EBITDA of 4.07 as of Aug. 04, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on China SXT Pharmaceuticals. This is near median its historical median of 4.28. Over the past decade, China SXT Pharmaceuticals' EV-to-EBITDA has ranged from 2.35 to 6.83. According to the industry distribution chart, China SXT Pharmaceuticals ranks #69 out of 746 companies in the Drug Manufacturers industry, placing it in the top 9.2%.
Is China SXT Pharmaceuticals' EV-to-EBITDA too high?
China SXT Pharmaceuticals' current EV-to-EBITDA of 4.07 is near median its 10-year median of 4.28. Over the past 10 years, this metric has ranged from a low of 2.35 to a high of 6.83. The Drug Manufacturers industry median EV-to-EBITDA is 13.08. China SXT Pharmaceuticals' value of 4.07 is 68.9% below this industry median. Based on the distribution chart, China SXT Pharmaceuticals ranks #69 out of 746 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does China SXT Pharmaceuticals' EV-to-EBITDA compare to CBIH and UPC?
According to the Drug Manufacturers industry distribution chart, China SXT Pharmaceuticals ranks #69 out of 746 companies for EV-to-EBITDA. This places China SXT Pharmaceuticals in the top 9% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.08. China SXT Pharmaceuticals' value of 4.07 is 68.9% below this benchmark. Historically, China SXT Pharmaceuticals' own EV-to-EBITDA has ranged from 2.35 to 6.83 over the past decade. While the company's 10-year median is 4.28 vs. the industry median of 13.08, China SXT Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.08, based on 746 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China SXT Pharmaceuticals's current EV-to-EBITDA of 4.07 is 68.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on China SXT Pharmaceuticals. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China SXT Pharmaceuticals's current EV-to-EBITDA is 4.07, which is near median its own 10-year median of 4.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China SXT Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, China SXT Pharmaceuticals (SXTC) is currently considered Possible Value Trap. The stock's GF Value™ is $2.05, compared to a current price of $0.07 — trading 96.6% below its estimated fair value. The current EV-to-EBITDA is 4.07, which is near median its 10-year median of 4.28 and 68.9% below the Drug Manufacturers industry median of 13.08. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For China SXT Pharmaceuticals (SXTC), the current EV-to-EBITDA is 4.07 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SXTC has been successfully added to your 
